Bill Lundberg

Bill Lundberg has had a long and varied career in the biopharmaceutical industry. In 2019, they became the President and CEO of Merus N.V. and a Director of Meridian Academy. Bill also became an Independent Director of Vor Biopharma and 1928 Diagnostics. In 2018, they became a Partner at Cold Spring Partners, LLC. In 2017, they became an Independent Director of Q32 Bio Inc. and a Board Member of the Alliance for Regenerative Medicine. In 2015, they became the Chair of the Scientific Advisory Board and the Chief Scientific Officer of CRISPR Therapeutics. In 2011, they became the Vice President of Translational Medicine at Alexion Pharmaceuticals. In 2010, they became the Chief Medical Officer of Taligen Therapeutics.

Bill Lundberg received their MD from Stanford University School of Medicine in 1990, their MBA from U Mass - Isenberg School of Management in 2007, and their BS Biology from Massachusetts Institute of Technology.